This is the authors' abstract. We don't add key points for this paper.
OBJECTIVES: Participant information leaflets (PILs) for early phase clinical trials typically state that there is no direct, or guaranteed, benefit to participants. However, comprehensive screening may identify undiagnosed or subclinical conditions, offering unintended but meaningful personal health benefits. This study aimed to quantify and characterise clinically significant abnormalities identified during trial screening. STUDY DESIGN: We conducted a retrospective cohort review of all participants screened for early phase trials at the NIHR Liverpool Clinical Research Facility from March 2016 to December 2024. METHODS: Clinical data were extracted from electronic case notes and reviewed by two consultants, with a third resolving discrepancies. Clinically significant abnormalities were defined as newly identified conditions that may require further investigation or intervention. Incidence rates and subsequent actions taken were analysed. RESULTS: Among 1158 completed screenings (622 healthy volunteers, 536 patients), 5·79% of healthy volunteers and 3·89% of patients had clinically significant abnormalities. Common conditions included cardiovascular and metabolic abnormalities. Some participants were diagnosed with serious conditions, such as lymphoma and Wolff-Parkinson-White syndrome. Of those with abnormalities, 38% still proceeded to trial dosing after clinical review. An additional 5·87% had abnormalities deemed non-significant after further assessment. CONCLUSIONS: Early phase trial screening identifies clinically significant health conditions in a meaningful proportion of participants, particularly healthy volunteers. These findings challenge the prevailing "no benefit" narrative in PILs and support more accurate, ethically nuanced consent language. Screening during trial participation may offer a legitimate, unintended public health benefit through earlier detection and intervention.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Dodd et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: